How to access Elrexfio from Kuwait — the named-patient import pathway, 2026
By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23
A Kuwaiti patient with relapsed or refractory multiple myeloma whose disease has progressed after multiple prior lines of therapy may be evaluated by their treating haematologist for Elrexfio (elranatamab-bcmm). Elrexfio is FDA-approved, developed by Pfizer, and is a BCMA×CD3 bispecific antibody — a subcutaneously administered immunotherapy that engages the patient's own T cells against BCMA-expressing myeloma plasma cells. In Kuwait, Elrexfio is not yet broadly registered, which is why your haematologist may be navigating a named-patient import pathway on your behalf.
This guide explains the pathway, what documentation your physician needs, typical timing and cost bands, and where Reserve Meds fits in.
The clinical situation
Elrexfio is administered as a subcutaneous injection on a step-up schedule to reduce cytokine release syndrome risk, followed by weekly and — in some labeling scenarios — a later transition to every-two-week maintenance dosing. Step-up is typically conducted in an inpatient or closely monitored haematology unit; subsequent doses transition to outpatient. Eligibility is based on prior line history, fitness for immune-engaging therapy, and access to a unit familiar with CRS and neurotoxicity monitoring. Your haematologist will confirm eligibility and coordinate the step-up admission.
Is Elrexfio legally importable into Kuwait?
Yes — through the Kuwait Ministry of Health (MOH) named-patient / compassionate-use import framework. The route allows a Kuwait-licensed physician, working through an accredited hospital pharmacy or the Central Medical Stores mechanism, to request import of a medicine not locally registered when: (a) the medicine has been approved by a recognised reference authority such as the US FDA, (b) no clinically equivalent locally registered alternative is suitable, (c) the treating physician takes clinical responsibility, and (d) chain of custody is documented end to end.
Kuwait has a long history of supporting advanced haematology and oncology access for its citizens, with a relatively streamlined named-patient mechanism for documented clinical need. Your haematology team will identify the correct MOH sub-committee for the application.
How the pathway works, step by step
- Consultation with your treating haematologist. Eligibility assessment including line history and fitness for bispecific therapy.
- Haematology unit coordination. The admitting unit confirms step-up admission capacity and CRS/neurotoxicity monitoring protocols.
- MOH named-patient application. Your physician or the hospital's importing pharmacy files the application with clinical rationale, patient identification, product details, and chain-of-custody plan.
- US-side sourcing. Reserve Meds coordinates with our US-licensed specialty wholesale partner to secure product from authorised distribution.
- Cold-chain shipment. The product ships with continuous temperature monitoring and chain-of-custody documentation end to end.
- Arrival, step-up admission, and ongoing dosing. The hospital pharmacy releases doses for the step-up and subsequent maintenance injections.
What documentation your physician needs
Your physician will typically need to provide:
- A clinical rationale letter confirming relapsed/refractory myeloma, line history, and Elrexfio as the indicated treatment
- Verification of their Kuwait medical licence (MOH)
- Identification of the admitting haematology unit and the CRS/neurotoxicity monitoring plan
- Patient identifier (Civil ID reference where required, anonymised elsewhere)
- Planned step-up schedule and maintenance dosing plan
Reserve Meds provides a physician documentation kit that bundles the templates Kuwait MOH reviewers expect to see, including the CRS/neurotoxicity surveillance plan that is a standing element for BCMA×CD3 bispecifics.
Costs and timing
Elrexfio's US cash-pay reference price is driven by vial size and dosing frequency. Indicative 2026 cost for a 4-week maintenance supply sits in a broad range of roughly USD 40,000–48,000, with total course cost driven by duration on therapy. Inpatient monitoring during step-up is a separate locally billed component. Cold-chain logistics, MOH documentation handling, and concierge coordination add incremental cost. Reserve Meds issues a full transparent quote at the start of intake.
Indicative timing — not guaranteed — for the first step-up dose after cohort intake opens is approximately 14–28 days from the moment a complete MOH application is submitted. Subsequent doses ship on a rolling basis against your dosing calendar.
Reserve Meds is in pre-launch. Fulfillment availability is limited to our first cohort, and all timelines published on this site are indicative. If your clinical situation is time-sensitive, flag that when you join the waitlist — we triage accordingly.
A culturally-aware note: Kuwaiti families often prefer to keep complex haematology care close to home. Our concierge model supports in-country delivery to your treating haematologist's hospital rather than requiring travel, where the hospital has the monitoring capability for bispecific step-up.
Reserve Meds's role
Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. For Elrexfio specifically, we provide:
- Sourcing. Through our US-licensed specialty wholesale partner, operating under DSCSA chain-of-custody.
- Documentation. Regulatory package for your physician and for Kuwait MOH review.
- Logistics. Cold-chain, temperature-monitored shipment coordination to your admitting facility.
- Concierge case lead. A named point of contact for the family and the physician through intake, step-up, and maintenance.
What we do not do: we are not the prescriber, we do not practise medicine, and we are not the dispensing pharmacy. All clinical decisions remain with your treating haematologist and the admitting unit. We operate on a waitlist basis during our pre-launch phase.
Frequently asked
Is this legal in Kuwait? Yes, when executed through the Kuwait MOH named-patient / compassionate-use framework with appropriate documentation. Kuwait has a long history of supporting advanced oncology and haematology access through this route. See our trust and compliance page.
What if there is a locally registered BCMA bispecific alternative? MOH reviewers assess whether a locally registered option is clinically equivalent for your case. Where it is not suitable — for example because of prior BCMA exposure, supply issues, or a specific profile need — the named-patient rationale is typically supported.
How long is the inpatient step-up? Step-up admission length varies by centre and patient response. Kuwait tertiary haematology units follow standing international protocols; your team will advise.
What about CRS and neurotoxicity? These are known class features of BCMA×CD3 bispecifics and are managed with the step-up schedule and standing monitoring protocols.
Will insurance or MOH reimbursement cover this? Some categories of Kuwaiti patients receive MOH or military health reimbursement consideration for named-patient oncology; we supply documentation for your submission but do not process insurance or public-payer claims directly.
Next step — join the first-cohort waitlist
Reserve Meds is opening to a limited first cohort in 2026. Add your case to the waitlist and our concierge case lead will reach out when we are ready to enter intake for Elrexfio coordination in Kuwait.
Add me to the Elrexfio waitlistComposite case examples. Reserve Meds is in pre-launch. This content is for general information and does not constitute medical advice.
Clinical & regulatory review: Reserve Meds clinical team and AI regulatory-counsel review pipeline. Last medically reviewed: 2026-04-23.